Skip to content

Delavirdine mesylate

DRUG18 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), Pharmacia and Upjohn, Hoffmann-La Roche, Bristol-Myers Squibb, Agouron Pharmaceuticals

Conditions

HIV Infections

Phase 1

Phase 2

A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients
WithdrawnNCT00001094
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Updated: 2015-03-09
A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
CompletedNCT00000803
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 1997-03-31Target: 471Updated: 2021-11-04
Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315
CompletedNCT00000891
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
End: 2004-05-31Target: 34Updated: 2021-11-04
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
TerminatedNCT00002420
Bristol-Myers SquibbHIV Infections
Target: 25Updated: 2008-08-14
Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects
CompletedNCT00000882
National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections
Target: 300Updated: 2013-07-29
A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies
CompletedNCT00002210
Pharmacia and UpjohnHIV Infections
Target: 24Updated: 2005-06-24

Phase 3

Unknown Phase